PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

• J.-M. Michot,
• Y. Koh,
• P. Lee,
• J. Jin,
• R. Clynes,
• S. Kye,
• M. Chiarella,
• K. Patel

Affiliations

J.-M. Michot

1 Hematology and Innovative Drugs, Institut de Cancérologie Gustave Roussy, Villejuif, France

Y. Koh

2 Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

P. Lee

3 Clinical Operations

J. Jin

4 Biostatistics, Xencor, Inc.

R. Clynes

5 Translational Biology, Xencor, Inc

S. Kye

6 Clinical Development, Xencor, Inc., San Diego

M. Chiarella

6 Clinical Development, Xencor, Inc., San Diego

K. Patel

7 Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, United States of America